Various agents have been applied topically to treat infected wounds for millennia, but their proper role remains unclear. Topical therapy affords many potential advantages but also has disadvantages. Opinions differ on which clinical signs define wound infection and on whether quantitative microbiological studies are useful. Clinically infected wounds usually require systemic antibiotic therapy, whereas clinically uninfected wounds that are healing as expected do not require antimicrobials. There is controversy over how to treat poorly healing wounds with "secondary" signs suggesting infection; these may benefit from topical antimicrobial agents. Some evidence supports using topical agents for malodorous or burn wounds. Metaanalyses and systematic reviews suggest there are few proven indications for topical antimicrobials. Use of a newer, relatively nontoxic antiseptic (eg, cadexomer iodine or silver dressings) is preferable to use of topical antibiotics, especially agents that are available for systemic use. We provide clinically relevant information on currently available topical antimicrobial agents.
bacterial infections, acne, noncutaneous (eg, optical, otic, or mucosal) conditions, or for hand hygiene or prophylaxis to prevent wound infection. We must begin by defining when a wound is infected.
HOW SHOULD WE DEFINE WOUND INFECTION?
Virtually all open wounds are colonized with microorganisms, but this usually has no clinical consequences, because they show no evidence of infection and heal as expected [5] . Some wounds are clearly infected; they have purulent secretions or some of the cardinal manifestations of inflammation (erythema, warmth, pain or tenderness, or induration) that have classically defined the host response to tissue damage caused by pathogenic and invasive microorganisms [6] . The likelihood that a wound will become infected is related directly to the inoculum size and virulence of the colonizing organisms and inversely related to local and systemic host resistance [7] . But some wounds occur in patients with neuropathy (which may obscure or cause pain), ischemia (which may reduce erythema, warmth, or induration), or venous insufficiency (which may mask warmth or cause in- NOTE. Data are from [12, 13] . a Diabetic foot, pressure, or venous stasis ulcers (77 chronic and 16 acute); several anaerobic organisms detected by molecular methods but none were isolated by culture [12] . b Specimens from 8 healing and 10 nonhealing chronic venous leg ulcers; 40% of species detected by molecular methods were not detected by standard culture [13] . c Specimens from 19 wounds (all but 1 of the lower extremity) [14] .
duration). Because these conditions limit the expression of inflammation, some define infection by "secondary" signs of local infection, (eg, nonpurulent exudate, discolored or friable [easily bleeding] granulation tissue, breakdown or "pocketing" at the wound base, or an abnormally foul odor) [6, 8] . A Delphi approach by an international group of 54 wound care experts produced consensus on criteria they deemed common to infection in all chronic wounds: "cellulitis," malodor, pain, delayed healing, deterioration or breakdown, and increased exudate [9] . Some of these criteria have purportedly been validated by studies of various wounds in several settings, but the findings are limited by the fact that they compare the clinical criteria to inadequately validated microbiological definitions of infection [10] . Furthermore, the "additional" (if not the "traditional") evidence of infection likely varies for different types of chronic wounds [6] . Others approach the diagnostic problem by defining infection microbiologically, suggesting that apparently uninfected but nonhealing wounds may demonstrate either "critical colonization" with certain virulent species or a heavy bacterial "bioburden," usually defined as у10 5 colony forming units per gram of tissue [11] . This concept remains controversial, and recent studies suggest it is less the density of organisms than the presence of particular species (eg, Pseudomonas aeruginosa, Peptostreptococcus species, or Morganella morganii) [11] , the diversity of bacteria, or the patient's response to colonization that lead to a nonhealing but uninflamed wound [2] . Cultures of wound specimens usually grow aerobic gram-positive cocci, which are often mixed with gram-negative bacilli and sometimes anaerobes, but molecular diagnostic studies have shown a greater microbial complexity than had previously been recognized (Table 1) . Furthermore, recent studies have demonstrated that, in many chronic wounds, bacteria persist in adhesive, polymeric matrix biofilm communities, in which they induce chronic inflammation that delays healing and that they are more resistant to antimicrobial therapy [15] . These findings have led to suggestions that, in wounds that are apparently properly treated but that fail to heal, the clinician should consider topical antimicrobials.
WHY CONSIDER TOPICAL THERAPY?
With many systemic antibiotics available, why consider topical antimicrobial therapy for an infected wound? Even if the in- fection remains confined to superficial tissues, it may cause delayed healing, exudation, or malodor. Although some wound infections will heal with no antimicrobial therapy, many-particularly in immunocompromised or anatomically compromised hosts-will progress to involve deeper tissues and potentially cause systemic infection. These processes are largely mediated by toxins and metabolic wastes produced by microorganisms but also by the host response to infection [16] . For millennia, healers have applied various compounds to infected wounds, some of which (eg, silver and honey) we still use today. Compared with systemic antibiotic therapy, topical application has many potential advantages, as well as some disadvantages, as outlined in Table 2 [17, 18] . To overcome known deficiencies, clinicians and industry have defined the ideal potential topical agent, as summarized in Table 3 [19] . Topical antimicrobials have traditionally been formulated as ointments, which are more occlusive, often contain petrolatum, and are best for dry lesions; and creams, which are less occlusive, wash off with water, are less messy, and are best for moist lesions. One gram of cream covers ∼100 cm 2 of skin, whereas ointments cover a 5%-10% larger area. Newer technologies incorporate antimicrobials into dressings, such as alginates, foams, and sponges, allowing controlled release at the wound surface. One major problem with topical therapies is that there are no specific tests of these agents that have been standardized and approved by any official oversight agency for evaluating their efficacy.
WHAT TYPES OF TOPICAL ANTIMICROBIALS ARE AVAILABLE?
Disinfectants are agents with activity against virtually all disease-causing microorganisms, including spores; they are used primarily for sterilizing inanimate surfaces and may be toxic to tissues. Most topical antimicrobials can be divided into 1 of 2 major groups:
• Antiseptics. Antiseptics are disinfectants that can be used on intact skin and some open wounds to kill or inhibit microorganisms. They often have multiple microbial targets, a broad antimicrobial spectrum, and residual anti-infective activity but are often toxic to host tissues (eg, fibroblasts, keratinocytes, and possibly leukocytes).
• Antibiotics. Antibiotics are chemicals produced either naturally (by a microorganism) or synthetically that in dilute solution inhibit or kill other microorganisms. They usually act on one specific cell target, have a narrower spectrum of activity, are relatively nontoxic, and are more susceptible to losing their effectiveness to bacterial resistance.
Antiseptics. These compounds have antibacterial and desloughing actions and are generally safe when applied to intact skin. Most agents can cause some toxicity to host cells in vitro, such as prolonging the acute inflammatory response or delaying the production of collagen, but these effects are not usually noted in vivo [16, 20] . Some older agents (eg, sodium hypochlorite and hexacholorphene) are now infrequently used for infected wounds. Commonly used antiseptics (see Table 4 ) include hydrogen peroxide, which has limited bactericidal and debriding activity; chlorhexidine, which has long-acting activity against a wide range of both gram-negative and gram-positive bacteria; and iodophors, which release free iodides but may be cytotoxic. Iodines have been used for 1150 years without bacteria developing resistance [21] . Newer formulations, such as cadexomer iodine, offer sustained delivery of bactericidal concentrations to moist wounds without apparent tissue damage. Silver compounds (metallic, nanocrystalline, and ionic) have a broad bactericidal spectrum and have enjoyed a recent resurgence as topical antiseptics in various types of wound dressings. Silver ions kill bacteria by several mechanisms, including damaging their cell walls, membranes, respiratory enzymes, and ribonucleoproteins [22, 23] . Because they are rapidly inactivated in the wound environment, they require a sustained delivery formulation. Silver has proven efficacy against several common wound pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and extended-spectrum b-lactamase producers. Resistance is rare but has been reported, mostly with gram-negative species [19] . Adverse effects are infrequent, and silver may be active against biofilm. Silver compounds in various wound products differ in the manner and speed with which they release the bactericidal silver ions [22] . Although silver dressings have been the subject of many anecdotal reports and case series, they have been used in few well-designed clinical trials. Another newly popular topical remedy for wound infections is honey. Its beneficial actions are related to the osmotic effect produced by the high sugar content but also to the presence of an enzyme that produces hydrogen peroxide, as well as to nonperoxide antibacterials [24] . Honey has an inhibitory effect on 150 species of bacteria, including clinical strains of MRSA and VRE, and there is no reported microbial resistance. It has demonstrated clinical effectiveness for various types of wound infections; dramatically decreases skin colonization with many bacteria, including MRSA [25] ; hastens wound healing; and rarely causes adverse reactions. Medical grade honey (eg, Manuka) is approved in many countries and there are several sterile, irradiated, antibacterial (Unique Manuka Factor-rated) brands available [24, 26, 27] . Clinicians should avoid using nonmedical honeys that may contain viable spores (including clostridia) and have unpredictable antibacterial activity.
Because chronic wounds are so common, it is not surprising that new agents are frequently introduced. Super-oxidized water is a recently approved antiseptic, one brand of which (Microcyn; Oculus) is available without prescription. This pH-neutral sterilant with reactive species of chlorine and oxygen in a stable formulation is rapidly bactericidal, has broad-spectrum coverage, does not appear to facilitate bacterial resistance or damage host tissues, and may be active in the presence of biofilm [28] . It can be applied directly to wounds or be combined with dressings or other wound products, and several small, nonrandomized studies suggest it is effective in treating infected diabetic foot ulcers [29] [30] [31] . Antimicrobial peptides are another novel approach to topical therapy. These small (!100-amino acid), cationic, amphipathic compounds are stored in granules of polymorphonuclear leukocytes and epithelial cells in most eukaryotes [32, 33] . They are rapidly bactericidal against a broad spectrum of organisms and synergistic with-although unrelated to-other antimicrobials. Acquired resistance rarely develops. Pexiganan, a peptide awaiting US Food and Drug Administration approval that is applied in a 1% cream, is bactericidal for most aerobic and anaerobic, gram-positive and gram-negative pathogens [34] [35] [36] , and there are no reports of cross-resistance to other antibiotics. In 2 randomized, controlled trials that enrolled patients with a mildly infected diabetic foot ulcer, topical pexiganan proved overall to be similarly effective clinically and microbiologically to oral ofloxacin, with fewer adverse events [37] .
Antibiotics. Clinically infected wounds should usually be treated with systemic antibiotic therapy. The first topical antibiotics were derived from agents developed for systemic use (ie, sulfonamides in the mid-1930s), followed in the next decade by topical penicillins, bacitracin, gramicidin, aminoglycosides (including neomycin), polymixin, tetracyclines, and choloramphenicol. Agents introduced later include fusidic acid, clindamycin, metronidazole, mupirocin and retapamulin. Only a few topical antibiotics are commonly used in the US (Table 5) . Neomycin is active against most aerobic gram-negative rods (excluding most Pseudomonas species) and staphylococci (but not most other gram-positive cocci); resistance develops relatively frequently, as does contact dermatitis. Polymixin is active against some gram-negative rods (including Pseudomonas species) but not gram-positive cocci; systemic absorption is uncommon, and dermatitis is rare. Bacitracin is active against most gram-positive organisms, and resistance and toxicity are uncommon. These 3 antibiotics are combined in a nonprescription ointment commonly used on wounds by patients and some providers. It is best to avoid using topical antibiotics that are available for systemic therapy when treating wound infections, because they can provoke delayed hypersensitivity reactions, favor superinfections, and select for resistant pathogens. One exception is metronidazole, which can reduce the fetid odor of (presumably) anaerobically colonized wounds [38] .
Antibiotics used only in topical formulations may be appropriate for treating some infected wounds. Mupirocin is active against aerobic gram-positive cocci (except enterococci) and has minimal toxicity, and cross-resistance is uncommon. Although it is sometimes used off-label for treating or decolonizing (especially if MRSA is present) chronic wounds [39] , published studies supporting this indication are lacking, and the incidence of resistance is increasing. Retapamulin, which was approved in 2007, is a 1% semisynthetic pleuromutilin compound with in vitro activity against most gram-positive bacteria (and anaerobes). Although it is indicated for impetigo in both the United States and the European Union, only the latter has also approved it for treating wounds (small lacerations, abrasions, or sutured wounds) infected with Streptococcus pyogenes or S. aureus (excluding MRSA strains). Although retapamulin has good in vitro activity against MRSA, it has not yet been proven to be clinically effective [40] . It has a low potential for organisms to develop resistance and has not shown cross-resistance to other antimicrobial classes. Retapamulin has been shown to be similar in efficacy to topical fusidic acid and to oral cephalexin for treating impetigo or infected traumatic lesions [40] [41] [42] , but there are no data on use of this agent for chronic wounds.
WHAT IS THE EVIDENCE FOR USING TOPICAL ANTIMICROBIALS FOR TREATING CHRONIC WOUNDS?
Available data make it difficult to assess the efficacy of topical antimicrobials for chronic wounds. Most studies are suboptimal and have varying designs that are not easily comparable. To start, specifications for in vitro testing of these agents are not standardized among countries [43] . Animal models also yield inconsistent evidence, depending on the experimental species, type of wound induced, and microorganisms used; many are probably irrelevant to chronic wounds in patients, who often have underlying medical conditions. Although the anecdotal reports and case series involving humans provide some information, clinical trials are the test of efficacy. Unfortunately, many of the published trials do not define the types of patients and wounds included, select inappropriate control groups, or have inadequate sample sizes. Because wound infection is illdefined, comparison of study outcomes is difficult. So what do the published clinical trials tell us about the efficacy of these agents? A 2001 systematic review of controlled trials of antimicrobial agents for chronic wounds (diabetic foot ulcers, pressure ulcers, chronic leg ulcers, etc.) found 30 studies (25 randomized trials) with a total of 1436 patients that met the inclusion criteria [44] . The authors concluded that few systemic agents improved outcomes, but several topical substances hastened healing, including silver-containing compounds for venous ulcers and oxyquinoline ointment for stage 1-2 pressure ulcers. A 2008 Cochrane systematic review of antibiotics and antiseptics for venous leg ulcers concluded that some evidence supports using topical cadexomer iodine, but further research is required to determine the effectiveness of povidone iodine, peroxide-based preparations, ethacridine lactate, and mupirocin for healing venous leg ulcerations [45] . Similarly, a 2008 systematic review of the effectiveness of various interventions for enhancing the healing of chronic diabetic foot ulcers found a single study that demonstrated no benefit of cadexomer-iodine in cavitary wounds and one suggesting that zinc oxide tape improved necrotic wounds more than a hydrocolloid [46] . A 2006 Cochrane review of silver-based wound dressings and topical agents for treating diabetic foot ulcers found no controlled trials that met basic design requirements and that reported outcomes on healing rates or infection resolution [47] . Likewise, a 2007 Cochrane review of silver-containing dressings or topical agents for treating infected or contaminated chronic wounds concluded there was insufficient evidence, on the basis of 3 randomized, controlled trials (each with a short follow-up duration), to recommend this treatment [48] . Use of honey for treating wounds was the subject of a 2008 Cochrane systematic review. On the basis of data from 19 trials (totaling 2554 patients) that met the inclusion criteria, the authors concluded that, compared with some conventional dressings, honey may reduce the healing time for mild-to-moderate superficial and partial thickness burns but did not significantly hasten leg ulcer healing; for other uses, there was insufficient evidence to guide clinical practice [49] .
WHAT CAN WE CONCLUDE ABOUT TOPICAL ANTIMICROBIAL THERAPY FOR CHRONIC WOUNDS?
Although some take strong positions on either side of the debate, most clinicians are confused about whether and when to use topical antimicrobials for chronic wounds and which topical antimicrobial to use. Wound care should always begin with ensuring adequate debridement, removal of any foreign bodies, pressure off-loading, and proper dressings, then assessing for (and treating when needed) any arterial or venous insufficiency, or metabolic derangements. Then, classify the wound to determine the approach to antimicrobial therapy (Table 6 ). Clinically infected wounds usually require systemic antibiotic therapy, with the exceptions mentioned previously. Topical antimicrobial therapy, although not currently advisable for most clinically uninfected chronic wounds, does have a role in specific circumstances. Evidence upholds its use for burn wounds in which blood vessels to the skin are often destroyed, both to prevent sepsis and help treat infection [50] . Some data support use of topical agents for eradicating wound bacteria prior to skin grafting or for reducing odor associated with nonhealing, necrotic wounds. Clinicians could consider adding topical antimicrobials, which achieve high local levels, to systemic antibiotics in a patient with an infected ischemic wound who cannot undergo revascularization. One can reasonably argue for trying a short course of a topical antiseptic (preferably one of the newer, safer preparations, such as iodine or silver dressings) for an otherwise properly managed wound that is failing to heal and has some secondary findings suggesting subclinical infection. Another potential application might be to help in the removal of biofilms, which have been implicated in persistent infections. Some in vitro tests of iodides, silver, and hydrogen peroxide (and, thus, peroxide-generating honey) compounds show inhibition or disruption of biofilm [43] . Topical treatments may also prove helpful with the increasing problem of multidrug-resistant organisms that are untreatable with most systemic agents. A recent study of 47 multidrug-resistant organisms from burn wounds found that most were susceptible to 11 commonly used topical antibiotics and antiseptics, although the rates of resistance were higher than to non-multidrug-resistant organisms [50] .
The main arguments against using topical antiseptics are the lack of adequate proof of efficacy and residual concerns about their potential toxicity to healing wounds. A compound's toxicity risk depends on the particular formulation, concentration of active ingredient, and duration of exposure. Newer formulations and methods of applying topical antiseptics appear to reduce the risk. Antiseptics should not be used in solutions, because they are more likely to cause cell damage and have no demonstrated benefit over saline irrigation [5] . Newer topical creams, ointments, gels, and dressings appear to provide adequate, sustained, and apparently nontoxic levels of antiseptics. Unfortunately, there is little information on systemic absorption of the agents, and evidence of clinical efficacy is meager. Thus, clinicians should currently use these products very selectively and only for a short duration. Investigators and the industry are seeking other ways to deal with chronic wound infections, including various innovative nonantimicrobial approaches. In light of the size and importance of the problem of chronic wound infection, we expect crude empiricism to continue to give way to creative entrepreneurship.
